Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors

doi:10.5306/wjco.v12.i9.746

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5636)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

359

WORD

135

HTML

3310

Figures (1-1)

283

Tables (1-2)

293

Sum=4380

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

395

Download

861

Sum=1256

Sep 24, 2021 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Sep 24, 2021; 12(9): 746-766
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.746

Table 2 Clinical studies applying plerixafor with granulocyte colony-stimulating factor ± chemotherapy for hematopoietic stem cells mobilization in patients with relapsed/refractory germ cell tumors

Ref.	Number of patients participating	Successful mobilization rates on previously failed chemotherapy + G-SCF driven mobilization (> 2 × 10⁶)	Mobilization techniques
Kobold et al[128] 2011 (Retrospective analysis)	6	66.67% (4)	Chemo + G-CSF failed
Kobold et al[128] 2011 (Retrospective analysis)	6	66.67% (4)	Plerixafor + G-CSF
Horwitz et al[162] 2012 (Retrospective analysis)	21	76% (17)	Chemo + G-CSF failed
Horwitz et al[162] 2012 (Retrospective analysis)	21	76% (17)	Plerixafor + G-CSF
Worel et al[163] 2012 (Retrospective analysis)	11	91% (10)	Plerixafor + G-CSF
Garcia-Escobar et al[164] 2014 (Case series)	5	80% (4)	Chemo + G-CSF failed
Garcia-Escobar et al[164] 2014 (Case series)	5	80% (4)	Plerixafor + G-CSF
Kosmas et al[165] 2014 (Pilot study)	14 (3)	100% (3)	Chemo + G-CSF failed
Kosmas et al[165] 2014 (Pilot study)	14 (3)	100% (3)	Chemo + Plerixafor + G-CSF
O’Hara et al[166] 2014 (Retrospective analysis)	9 (3)	100% (3)	Plerixafor + G-CSF

Related case studies: Saure et al[167], 2010; Tuffaha and Adel-Rahman[168], 2011; De Blasio et al[169], 2013; Miltiadous et al[170], 2017. G-CSF: Granulocyte colony-stimulating factor.

Citation: Porfyriou E, Letsa S, Kosmas C. Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors. World J Clin Oncol 2021; 12(9): 746-766
URL: https://www.wjgnet.com/2218-4333/full/v12/i9/746.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i9.746